|
|
Article: The First Major Launch of a Cancer Vaccine, Designed to Prevent Human Papillomavirus and Therefore Cervical Cancer, is Expected in 2006.
- Article from:
- Business Wire
- Article date:
- January 27, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c31753) has announced the addition of Outlook for Cancer Vaccine Development to their offering.
The incorporation of monoclonal antibodies into oncology therapy regimens has created an environment of acceptance toward new biologic therapies. Developers of cancer vaccines will be able to use this acceptance to establish these treatments as viable therapeutic options. The first major launch of a cancer vaccine, designed to prevent human papillomavirus and therefore cervical cancer, is expected in 2006.
In this report, the unmet needs in the cancer therapeutic market are ...
Related newspaper, magazine, and journal articles:
|
|
Article: Cancer Vaccines Taniguchi, F.; Yamagishi, H.; ...
Gene Therapy Weekly;
January 11, 1999 ;
535 words
... ... therapeutic effect of TNF gene-transduced cancer vaccine and whether the vaccination effect ... murine model. TNF gene-transduced cancer vaccine or systemic administration of rIL ... therapy using TNF gene-transduced cancer vaccine and rIL-12." The corresponding ...
|
|